Yabao Pharmaceutical Group Co., Ltd. (600351.SS) researches, develops, manufactures and sells Chinese and Western medicines, active pharmaceutical ingredients, pharmaceutical packaging materials and health products primarily in China and select international markets; its core offerings encompass pediatric products such as Ding Guier umbilical patch, barley bud spleen-strengthening gel and children's throat cleansing antipyretic oral solution; cardiovascular and cerebrovascular medicines including Zhenju antihypertensive tablets, nimodipine tablets and betahistine hydrochloride injections; endocrine treatments like nifedipine sustained-release tablets, lipoic acid tablets and thioctic acid injections; women's health solutions such as gynosteine dispersible tablets; general health items including vitamin C effervescent tablets and zinc gluconate oral solution; and dosage forms spanning light pastes, tablets, injections, capsules and oral liquids. Founded in 1978 and headquartered in Yuncheng, Shanxi Province, China, at No. 1 Gongye Boulevard, Fenglingdu Economic Development Zone, the company operates through multiple subsidiaries and branches with over 3,600 employees, focusing on chronic disease treatments for the elderly, women and children while maintaining a robust R&D pipeline in innovative traditional Chinese medicines, modified new drugs and pediatric therapies. In recent developments, Yabao Pharmaceutical Group signed a technology transfer agreement for a new Chinese medicine project, obtained clinical trial approval for new indications of the SY-005 project, terminated the long-term SY-009 Type 2 diabetes oral drug development after investing CNY 87.9 million and announced impairment preparations, released its 2025 semi-annual report, reduced registered capital, repurchased shares including 2 million shares for CNY 13.27 million from October to November 2025, and plans to sell 62% equity in a subsidiary expected to boost 2025 total profit by CNY 59 million. The company sustains ongoing R&D in diabetes and lipid-lowering areas with products like Sitagliptin Metformin Extended-Release Tablets, Alogliptin Benzoate Tablets, Gynostemma Pentaphyllum Total Glycosides Dispersible Tablets and pipelines including Ezetimibe Tablets and Trelagliptin Tablets, alongside prior strategic partnerships such as with Lupin in 2022 for pediatric formulations.